Loading...

Recombinant Human Acid Sphingomyelinase as an Adjuvant to Sorafenib Treatment of Experimental Liver Cancer

BACKGROUND: Hepatocellular carcinoma (HCC) is the most common form of liver cancer and the third leading cause of cancer death worldwide. The only approved systemic treatment for unresectable HCC is the oral kinase inhibitor, sorafenib. Recombinant human acid sphingomyelinase (rhASM), which hydrolyz...

Full description

Saved in:
Bibliographic Details
Main Authors: Savić, Radoslav, He, Xingxuan, Fiel, Isabel, Schuchman, Edward H.
Format: Artigo
Language:Inglês
Published: Public Library of Science 2013
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3665770/
https://ncbi.nlm.nih.gov/pubmed/23724146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0065620
Tags: Add Tag
No Tags, Be the first to tag this record!